Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | RACE: evaluating eltrombopag in severe aplastic anemia

Regis Peffault de Latour • 3 Sep 2020
EBMT 2020
Anemias Aplastic Anemia Cyclosporine Eltrombopag Horse antithymocyte globulin
Race

Régis Peffault de Latour, MD, PhD, Saint-Louis Hospital, Paris, France, presents results from the RACE trial (NCT02099747), a prospective, randomized multicenter study comparing horse antithymocyte globulin and cyclosporine A with or without eltrombopag as front-line therapy for severe aplastic anemia patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Regis Peffault de Latour

Overview of HSCT and GvHD at EBMT
1:17
Overview of HSCT and GvHD at EBMT
Regis Peffault de Latour • 3 Sep 2020
Eltrombopag for aplastic anaemia in Europe
2:01
Eltrombopag for aplastic anaemia in Europe
Regis Peffault de Latour • 1 Sep 2020
Iptacopan for paroxysmal nocturnal hemoglobinuria
2:21
Iptacopan for paroxysmal nocturnal hemoglobinuria
Regis Peffault de Latour • 2 Sep 2020
Aplastic anemia: EHA highlights
1:01
Aplastic anemia: EHA highlights
Regis Peffault de Latour • 15 Jun 2019

Related Videos

Managing ruxolitinib-associated anemia in myelofibrosis: dose reduction and add-on therapies
1:48
Managing ruxolitinib-associated anemia in myelofibrosis: dose reduction and add-on therapies
Ciro Rinaldi • 10 Sep 2026
Beyond JAK inhibitors: emerging approaches to anemia management in myelofibrosis
4:29
Beyond JAK inhibitors: emerging approaches to anemia management in myelofibrosis
Prithviraj Bose • 18 Sep 2026
Distinguishing disease- and treatment-related anemia in myelofibrosis
1:42
Distinguishing disease- and treatment-related anemia in myelofibrosis
Aaron Gerds • 21 Sep 2026
Insights into the evolving treatment paradigm for myelofibrosis beyond spleen and symptom control
1:16
Insights into the evolving treatment paradigm for myelofibrosis beyond spleen and symptom control
Haifa Kathrin Al-Ali • 13 Jun 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals